chronic
hepat
c
viru
hcv
infect
associ
chronic
inflamm
liver
lead
develop
cirrhosi
hepatocellular
carcinoma
hcc
sever
side
effect
cure
rate
genotyp
hcvinfect
patient
upon
current
standard
treatment
pegyl
interferona
plu
ribavirin
new
therapeut
regimen
still
need
sanhuangxiexintang
shxt
transit
chines
herbal
formula
compos
rhei
rhizoma
scutellaria
radix
coptidi
rhizom
possess
antiinflammatori
effect
describ
catechincontain
fraction
extract
shxt
refer
shxtfrc
exhibit
effect
inhibit
hcv
replic
select
index
valu
si
cc
ec
display
synergist
antihcv
effect
combin
interferona
hcv
proteas
inhibitor
telaprevir
polymeras
inhibitor
activ
factorjb
nfjb
signal
pathway
particular
relev
hcvassoci
hcc
shxtfrc
treatment
also
caus
concentrationdepend
decreas
induct
nfjb
express
caus
either
hcv
replic
hcv
protein
collect
shxtfrc
could
adjuv
treatment
patient
hcvinduc
liver
diseas
approxim
million
peopl
worldwid
persist
infect
hepat
c
viru
hcv
associ
chronic
inflamm
liver
emerg
lead
caus
fibrosi
cirrhosi
hepatocellular
carcinoma
vaccin
effect
hcv
addit
sever
side
effect
current
treatment
pegyl
interferona
pegifna
plu
ribavirin
includ
depress
fatigu
flulik
symptom
haemolyt
anaemia
often
lead
discontinu
treatment
therebi
warrant
need
develop
novel
drug
higher
efficaci
favour
side
effect
profil
treat
hcv
infect
hepat
c
viru
envelop
positivestrand
rna
viru
belong
hepaciviru
genu
within
flavivirida
famili
genom
encod
singl
polyprotein
subsequ
cleav
host
viru
proteas
least
matur
individu
protein
four
structur
protein
c
six
nonstructur
protein
among
latter
promot
improp
upregul
hepat
nuclear
transcript
factorkappab
nfjb
signal
pathway
lead
chronic
inflamm
prolifer
hepatoma
cell
induc
enzym
involv
product
variou
prostaglandin
pg
upon
exposur
multipl
stimuli
viral
bacteri
product
includ
lipopolysaccharid
cytokin
oncogen
mitogen
growth
factor
howev
aberr
upregul
express
contribut
progress
hepat
carcinogenesi
elev
pg
concentr
promot
cell
prolifer
surviv
inhibit
proapoptosi
pathway
ultim
result
tumour
format
recent
variou
studi
report
elev
protein
level
favour
increas
hcv
replic
although
exact
mechan
remain
elucid
basi
find
attract
mean
minim
hcvrelat
liver
malign
elimin
signal
pathway
simultan
reduc
viral
infect
hepatocarcinogenesi
sanhuangxiexintang
shxt
commonli
use
tradit
chines
medicin
formula
compos
rhei
rhizoma
rheum
officinal
baill
scutellaria
radix
scutellaria
baicalensi
georgi
coptidi
rhizom
copti
chinensi
franch
shxt
possess
varieti
bioactiv
includ
hypotens
effect
antiinflammatori
effect
cardiovascular
effect
gastric
protect
antioxid
activ
neuron
protect
immunomodulatori
effect
shxt
use
clinic
treatment
human
diseas
hypertens
gastriti
gastric
bleed
peptic
ulcer
sever
year
current
number
studi
demonstr
shxt
herbal
compon
possess
antihepatocellular
carcinoma
activ
suggest
shxt
potenti
agent
sever
marker
compound
shxt
baicalin
wogonin
possess
antivir
activ
respiratori
syncyti
viru
rsv
hepat
b
viru
sever
acut
respiratori
syndrom
coronaviru
infect
influenza
viru
howev
date
antihcv
activ
constitu
shxt
document
therefor
present
studi
assess
inhibitori
effect
hcv
replic
synergist
antihcv
activ
combin
variou
inhibitor
use
cellbas
hcv
replicon
system
extens
chemotherapeut
carcinogenesi
inhibitori
effect
shxt
extract
improp
induct
nfjb
express
caus
hcv
replic
aetiolog
hcv
protein
evalu
find
may
contribut
better
treatment
regimen
patient
chronic
hcv
infect
dri
shxt
offer
sun
ten
pharmaceut
co
ltd
taipei
taiwan
three
tradit
chines
medicin
identifi
r
officinal
baicalensi
copti
chinesi
microscop
highperform
liquid
chromatographi
hplc
fingerprint
profil
sun
ten
pharmaceut
co
ltd
interferonalfa
ifna
roferon
purchas
roch
ltd
san
francisco
ca
usa
telaprevir
purchas
toronto
research
chemic
inc
acm
bioscienc
belmont
ca
usa
respect
store
mm
dimethylsulphoxid
dmso
catechin
purchas
sigma
st
loui
mo
usa
final
concentr
dmso
reaction
maintain
constantli
experi
mixtur
r
officinal
baicalensi
c
chinesi
blend
ratio
total
kg
extract
three
time
use
meoh
meoh
extract
g
partit
h
ethyl
acet
ea
obtain
h
fraction
g
ea
fraction
g
fifti
gram
ea
fraction
subject
normalphas
flash
column
chromatographi
elut
ch
cl
eameoh
gradient
solvent
system
five
subfract
isol
thin
layer
chromatographi
among
subfract
g
isol
reversephas
chromatographi
elut
meohh
gradient
solvent
system
seven
subfract
separ
reversephas
chromatographi
final
catechincontain
fraction
term
shxtfrc
approxim
mg
obtain
subfract
reversephas
chromatographi
meohh
catechin
elucid
h
c
nuclear
magnet
reson
nmr
spectra
chromatograph
analysi
shxtfrc
isol
shxtfrcc
shxtfrcr
jasco
pump
jayte
bioscienc
ltd
hern
bay
kent
uk
jasco
detector
jayte
bioscienc
ltd
ascenti
ascenti
lancast
uk
lm
mm
column
supelco
employ
shxtfrc
hplc
analysi
isocrat
elut
perform
meohh
vv
flow
rate
mlmin
solvent
filter
filter
prior
use
eluent
detect
nm
data
analys
seri
version
softwar
shimadzu
kyoto
japan
purifi
shxtfrc
fraction
verifi
activ
compon
isol
condit
describ
previous
shxtfrcc
shxtfrcr
collect
shown
fig
human
hepatoma
cell
cell
kindli
provid
dr
charl
rice
rockefel
univers
new
york
usa
cultur
modifi
medium
heatinactiv
foetal
bovin
serum
antibioticantimycot
nonessenti
amino
acid
cell
line
harbour
hcv
subgenom
replicon
rna
maintain
complet
media
contain
mgml
code
sequenc
amplifi
polymeras
chain
reaction
pcr
plasmid
contain
cdna
hcv
strain
clone
express
vector
pcdna
invitrogen
carlsbad
ca
usa
design
promot
fragment
amplifi
human
genom
dna
describ
insert
promoterless
luciferas
vector
promega
co
madison
wi
usa
design
pnfjbluc
report
vector
measur
nfjb
transcript
activ
stratagen
la
jolla
ca
usa
clone
dna
fragment
verifi
dna
sequenc
total
cellular
rna
isol
use
total
rna
miniprep
purif
kit
hopegen
biotechnolog
develop
enterpris
taiwan
accord
instruct
northern
hybrid
perform
previous
describ
quantit
realtim
rtpcr
rtqpcr
perform
measur
mrna
hcv
gapdh
previous
describ
infecti
hcv
particl
hcvcc
gener
transfect
vitrotranscrib
genom
rna
cell
describ
cell
seed
densiti
cellswel
cultur
plate
infect
hcvcc
multipl
infect
h
follow
incub
variou
concentr
shxtfrc
catechin
addit
h
subsequ
total
rna
collect
subject
rtqpcr
measur
mrna
hcv
gapdh
describ
previous
western
blot
perform
describ
previous
membran
probe
either
antibodi
abcam
cambridg
usa
antigapdh
antibodi
genetex
ca
usa
anticmyc
antibodi
genetex
irvin
ca
usa
cell
viabil
determin
mt
assay
celltit
aq
ueou
one
solut
cell
prolifer
assay
system
promega
describ
previous
cell
treat
serial
dilut
shxtfrc
lgml
combin
serial
dilut
ifna
uml
hcv
rnadepend
rna
polymeras
nucleosid
inhibitor
lm
hcv
proteas
telaprevir
lm
day
level
hcv
subgenom
rna
measur
quantit
realtim
rtpcr
rtqpcr
previous
describ
multipl
drug
combin
data
determin
use
softwar
base
method
chou
talalay
biosoft
cambridg
uk
compar
singl
multipl
drug
doseeffect
determin
presenc
antagon
combin
index
ci
addit
ci
synerg
ci
ci
calcul
effect
concentr
ec
ec
ec
present
herein
transfect
luciferas
activ
assay
day
cell
lysat
prepar
luciferas
activ
use
brightglo
luciferas
assay
system
promega
western
blot
analysi
follow
instruct
cell
seed
plate
densiti
treat
shxtfrc
variou
concentr
day
incub
cell
harvest
cell
membran
lyse
releas
intracellular
pge
pge
express
level
detect
pge
enzymelink
immunosorb
assay
system
biotrak
amersham
bioscienc
accord
protocol
data
present
mean
sd
least
three
independ
experi
statist
analysi
carri
ttest
pvalu
consid
signific
blackwel
publish
ltd
jc
lee
et
al
base
bioassayguid
fraction
isol
subfract
shxt
design
shxtfrc
display
effect
inhibitori
action
hcv
protein
express
fig
lane
hplc
trace
shxtfrc
shown
fig
accord
analysi
hplc
profil
nmr
spectra
major
compon
shxtfrc
fraction
identifi
catechin
retent
time
catechin
shxtfrc
found
min
ident
standard
catechin
hplc
condit
subsequ
shxtfrcc
major
peak
harbour
catechin
shxtfrcr
residu
eluent
harbour
two
minor
peak
individu
collect
examin
antihcv
activ
base
calcul
peak
area
seri
version
softwar
shimadzu
amount
shxtfrcc
shxtfrcr
repres
shxtfrc
respect
princip
standard
herbal
extract
shxtfrc
cautious
prepar
base
catechin
fraction
marker
identifi
constitu
shxtfrc
contribut
antihcv
activ
cell
harbour
hcv
subgenom
rna
replicon
design
cell
treat
variou
elut
concentr
lgml
day
subsequ
cell
lysat
subject
western
blot
antihcv
antibodi
level
gapdh
serv
load
control
shown
notabl
inhibitori
effect
hcv
protein
synthesi
conserv
shxtfrcc
combin
shxtfrcr
lane
confirm
shxtfrcr
contain
bioactiv
constitu
hcv
protein
synthesi
current
data
unabl
clearli
discrimin
individu
constitu
shxtfrcr
use
shxtfrc
mixtur
investig
antihcv
activ
report
treatment
equal
ratio
commerci
avail
catechin
serv
intern
control
experi
thu
elimin
biolog
interfer
catechin
antihcv
activ
assay
confirm
antivir
activ
shxtfrc
northern
blot
quantit
rtpcr
rtqpcr
perform
specif
probe
primer
correspond
hcv
respect
level
cellular
gapdh
gene
serv
load
control
shown
fig
b
white
bar
clear
dosedepend
decreas
hcv
rna
level
occur
upon
treatment
shxtfrc
day
compar
treatment
mock
control
cell
dmso
calcul
effect
concentr
ec
defin
compound
concentr
reduc
hcv
rna
level
lgml
measur
rtqpcr
analysi
b
lgml
hcv
replic
decreas
toxic
observ
b
white
bar
hcv
rna
level
remain
unchang
presenc
catechin
lgml
b
black
bar
cytotox
index
shxtfrc
evalu
mt
cytotox
concentr
cc
defin
compound
concentr
result
cell
death
lgml
c
yield
high
select
index
valu
si
cc
ec
similarli
antihcv
activ
shxtfrc
also
observ
hcv
infecti
system
ec
valu
lgml
fig
white
bar
data
support
conclus
shxtfrc
promis
antihcv
agent
warrant
studi
next
investig
whether
combin
ifna
proteas
inhibitor
telaprevir
polymeras
inhibitor
would
produc
synergist
effect
inhibit
hcv
replic
cell
treat
shxtfrc
combin
antihcv
agent
variou
concentr
combin
index
ci
valu
effect
concentr
ec
ec
inhibit
ec
calcul
use
program
ci
valu
indic
degre
interact
potenti
drug
valu
indic
synergist
addit
antagonist
effect
respect
hcv
hepat
c
viru
shxt
sanhuangxiexintang
describ
materi
method
section
effect
combin
calcul
use
isobologram
method
comput
program
shown
tabl
combin
shxtfrc
individu
inhibitor
synergist
inhibit
hcv
replic
reveal
ci
valu
ec
ec
ec
rang
appar
cytotox
observ
test
concentr
combin
mt
analysi
prevent
effect
standard
shxt
report
abl
inhibit
lipopolysaccharidesinduc
inflammatoryassoci
gene
express
includ
nfjb
prostaglandin
pge
product
test
whether
hcvinduc
express
influenc
shxtfrc
cell
transfect
plasmid
carri
firefli
luciferas
driven
promot
day
presenc
increas
concentr
shxtfrc
shown
fig
dosedepend
reduct
prostaglandin
pge
product
shxtfrc
day
treatment
intercellular
pge
level
assay
biotrak
pge
enzym
immunoassay
system
amersham
indic
treatment
dimethylsulphoxid
valu
repres
mean
sd
triplic
experi
symbol
repres
statist
signific
pvalu
symbol
repres
statist
signific
pvalu
fig
inhibitori
effect
sanhuangxiexintang
shxt
frc
hepat
c
viru
hcv
induc
nfjb
promot
activ
hcv
replicon
cell
pnfjbluctransfect
cell
treat
indic
concentr
either
shxtfrc
catechin
day
cell
lysat
subject
luciferas
activ
assay
luciferas
activ
pnfjbluctransfect
cell
without
drug
treatment
serv
basal
control
induc
nfjb
promot
activ
defin
h
shxtfrc
catechin
valu
repres
mean
sd
triplic
experi
symbol
repres
statist
signific
pvalu
symbol
repres
statist
signific
pvalu
catechin
signific
effect
gene
express
black
bar
subsequ
western
blot
perform
confirm
effect
shxtfrc
suppress
express
consist
result
promoterbas
report
assay
shxtfrc
reduc
protein
level
concentrationdepend
manner
fig
contrast
catechin
result
signific
reduct
protein
level
fig
addit
activ
presenc
shxtfrc
quantifi
use
biotrak
pge
enzym
immunoassay
result
show
level
pge
decreas
concentrationdepend
manner
fig
nfjb
activ
one
ubiquit
mediat
activ
viral
infect
therefor
perform
promoterbas
assay
determin
whether
suppress
relat
modul
transcript
factor
nfjb
upon
shxtfrc
treatment
cell
transient
transfect
cisreport
plasmid
pnfjbluc
follow
transfect
cell
incub
without
shxtfrc
day
shown
fig
luciferas
activ
assay
reveal
shxtfrc
significantli
inhibit
nfjbmediat
transcript
activ
concentrationdepend
manner
white
bar
support
possibl
suppress
nfjb
may
involv
effect
shxtfrc
expect
catechin
affect
nfjbmediat
transcript
activ
black
bar
shxtfrc
attenu
nfjb
activ
hepat
c
viru
cell
hepat
c
viru
protein
shown
oncogen
potenti
link
stimul
nfjb
express
differ
mechan
examin
whether
shxtfrc
abl
block
express
prevent
hepatocarcinogenesi
express
vector
cotransfect
report
vector
parent
cell
absenc
presenc
shxtfrc
catechin
transfect
alon
serv
basal
promot
activ
day
luciferas
activ
measur
shown
fig
shxtfrc
markedli
inhibit
promot
activ
concentrationdepend
manner
white
bar
catechin
inhibit
promot
activ
induc
black
bar
subsequ
extend
studi
examin
whether
inhibitori
effect
shxtfrc
mediat
nfjb
activ
plasmid
cotransfect
nfjb
promot
plasmid
pnfjbluc
cell
absenc
presenc
shxtfrc
catechin
day
transfect
pnfjbluc
alon
serv
basal
promot
activ
nfjb
result
luciferas
assay
show
nfjb
promot
activ
markedli
suppress
shxtfrc
concentrationdepend
manner
fig
white
bar
contrast
catechin
inhibit
nfjb
promot
activ
black
bar
equal
express
condit
confirm
western
blot
analysi
use
antimyc
antibodi
fig
b
b
c
data
show
shxtfrc
effect
target
nfjb
express
impli
shxtfrc
potenti
prevent
virusinduc
hepatocarcinogensi
studi
extend
bioactiv
shxt
hcv
caus
agent
hepatocarcinogensi
demonstr
activ
extract
shxtfrc
deriv
herbal
medicin
shxt
possess
effect
antihcv
activ
fig
analys
bioactiv
constitu
shxtfrc
find
catechin
major
compon
shxtfrc
signific
antihcv
activ
concentr
lgml
fig
consist
result
recent
obtain
li
et
al
demonstr
singl
catechin
epicatechin
show
neglig
inhibitori
effect
hcv
replic
even
high
concentr
lm
approxim
lg
ml
format
dimer
catechin
epicatechin
design
procyanidin
requisit
antihcv
activ
howev
observ
controversi
taken
observ
report
takeshita
et
al
demonstr
catechin
extract
blueberri
leaf
suppress
hcv
rna
synthesi
ec
lgml
diverg
result
may
attribut
differ
geometr
isom
catechin
catechin
catechin
isol
studi
takeshita
et
al
develop
effect
treatment
option
improv
sustain
virolog
respons
toler
treatment
durat
sever
directact
antivir
agent
telaprevir
hcv
proteas
inhibitor
nucleosid
hcv
polymeras
inhibitor
examin
clinic
trial
howev
increas
drug
resist
becom
obstacl
success
therapeut
intervent
present
studi
provid
effect
safe
shxtfrc
extract
synergist
inhibit
hcv
replic
combin
chemotherapeut
agent
interferona
hcv
replicon
system
tabl
could
greatli
reduc
potenti
resist
side
effect
includ
combin
therapi
aetiolog
protein
hcv
includ
structur
protein
core
nonstructur
protein
particularli
markedli
modul
activ
nfjb
appear
turn
promot
hcv
replic
recent
downregul
hcvinduc
express
consid
molecular
mechan
involv
inhibitori
effect
hcv
replic
use
select
inhibitor
includ
acetylsalicyl
acid
inhibitor
iii
whether
antihcv
activ
shxtfrc
depend
downregul
nfjb
investig
addit
modul
activ
nfjb
shown
increas
replic
western
blot
antimyc
antigapdh
load
control
antibodi
respect
luciferas
activ
report
plasmid
transfect
cell
without
transfect
drug
treatment
serv
basal
control
induc
promot
activ
defin
reduct
luminesc
compar
signal
mocktreat
dimethylsulphoxid
cell
repres
mean
fold
reduct
triplic
experi
symbol
repres
statist
signific
pvalu
symbol
repres
statist
signific
pvalu
number
virus
cytomegaloviru
herpesviru
rsv
enteroviru
although
detail
mechan
clearli
defin
moreov
also
found
tumour
necrosi
factor
tnf
alphainduc
activ
nfjb
promot
also
inhibit
shxtfrc
data
shown
consequ
block
nfjbmediat
pathway
shxtfrc
fig
also
may
provid
potenti
agent
chemoprevent
viru
infect
conclus
first
demonstr
shxtfrc
effect
inhibit
hcv
replic
display
synergist
antihcv
activ
combin
variou
hcv
inhibitor
moreov
shxyfrc
inhibit
improp
induct
nfjb
express
caus
either
hcv
replic
aetiolog
protein
therefor
shxtfrc
may
serv
potenti
supplementari
treatment
patient
chronic
hepat
c
simultan
attenu
viral
replic
inflamm
carcinogenesi
close
correl
aberr
activ
nfjb
express
